Full-Time

Digital OR Integration Specialist

Posted on 7/5/2026

Brainlab

Brainlab

1,001-5,000 employees

Medical software and hardware for surgeries

Compensation Overview

$70k - $80k/yr

United States

In Person

Must reside near a major eastern-time airport; travel up to 80% with occasional nights/weekends.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Oscilloscope

Get referred to Brainlab

See people who can refer or advise you

Requirements
  • B.S. in Electrical Engineering, Biomedical Engineering, Mechanical Engineering or Information Technology Technology (IT Technology) required; Applicants without a 4 year degree must have minimum 4 years OR Integration installation experience or comparable skill set; Works well in a team environment and individually, delivering results without close supervision; Computer expertise, familiarity, and demonstrated expertise with hardware troubleshooting; Must be able to adjust to technical and logistics needs of a fast paced and dynamic environment; Able to apply critical thinking and perform analysis successfully under challenging conditions in a construction environment; Proficiency in the use of test equipment and hand tools including oscilloscopes and multi-meters; Excellent organization and time management skills, and the ability to manage many work streams simultaneously; Excellent written and oral communication skills; Professional and confident demeanor; Proactively approaches his/her contribution to the organization; Must be able to lift 50 pounds and work on ladders; Ability to travel 80%; Ability to work nights and weekends occasionally.
Responsibilities
  • Perform custom installations to establish functionality of OR Integration and Ceiling-Mounted Image Guided-Surgery Products. Work includes pulling cables (fiber and non-fiber), terminating cables, mounting hardware such as monitors and testing all cross-compatibility as per the scope of work for each project.
  • Perform repairs and periodic maintenance on OR Integration and Ceiling-Mounted Image Guided-Surgery Products
  • Functions rely upon knowledge & experience of Healthcare Data Management, HIPAA, VNA/HIS/PACS Integration, IHE, DICOM, HL7, 4K & Video Routing & Medical Device Integration
  • Relevant medical & integrated components include: Computer Workstation, Server, Virtual Environment, Video to Data Encoder & Decoder, Audio Amplifier & Mixer, Network Switch, Fiber Cabling, Copper Cabling & other components
  • Read, analyze, and interpret site planning manual and blueprints that contain infrastructure requirements, A/V system flow schematics, and wiring diagrams.
  • Resolve product issues through detailed analysis and utilization of engineering/troubleshooting expertise.
  • Effectively communicate with Project Management, Sales, Marketing and Clinical End Users to understand complex problems and adequately troubleshoot issues.
  • Instruct fellow team members & clinical end users in maintenance of OR Integration & Ceiling-Mounted Image Guided-Surgery equipment.
  • Deliver and Maintain high quality communication to internal & external customers.
  • Keep abreast of new developments regarding Brainlab and competitive OR Integration & Image Guided-Surgery products and services through training and analysis, as required.
Desired Qualifications
  • Knowledge of OR Integration technology and computer networks preferred
  • High comfort level with software and technology, in general

Brainlab is a medical technology company that creates software and hardware to improve surgeries, radiosurgery treatments, and operating room efficiency. It serves hospitals and clinics by providing digital tools that enhance surgical precision and patient outcomes. The core products include image-guided navigation, planning software, and connected hardware that work together to guide procedures. Revenue comes from selling software licenses, hardware devices, and ongoing subscription services that include updates and support. The company differentiates itself by offering integrated digital medical technologies that combine software and hardware for a seamless clinical workflow, backed by service agreements. Its goal is to help healthcare providers perform safer, more accurate procedures and run operating rooms more efficiently through data-driven tools and ongoing support.

Company Size

1,001-5,000

Company Stage

Early VC

Total Funding

$7.3M

Headquarters

Munich, Germany

Founded

1989

Get referred to Brainlab

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Brainlab grew 2024/25 revenue 6.8% to €492.5 million and kept hiring.
  • July 2026 KIMS Bengaluru became South Asia's first Brainlab functional neurosurgery reference center.
  • February 2026 Precision NeuroMed partnership opens a new AI drug-delivery planning market.

What critics are saying

  • Brainlab canceled its July 2025 Frankfurt IPO; private-capital dependence persists through August 2026.
  • Precision NeuroMed and Nexstim tie capital to clinical bets that can miss regulatory timelines.
  • Siemens Healthineers, Medtronic, and Elekta can bundle broader platforms and squeeze Brainlab margins.

What makes Brainlab unique

  • Brainlab spans planning, navigation, imaging, and OR workflow across 4,000 hospitals.
  • Its FDA-cleared mixed reality spine navigation deepens surgeon-facing visualization beyond standard optical systems.
  • Brainlab pairs software with hardware, creating sticky installed workflows and recurring service revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Conference Attendance Budget

Professional Development Budget

Wellness Program

Mental Health Support

Stock Options

Company Equity

401(k) Retirement Plan

401(k) Company Match

Phone/Internet Stipend

Home Office Stipend

Health Insurance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
MarketScreener
May 25th, 2026
Nexstim raises $4.3M from Eiffel and Brainlab, registers 840,000 new shares

Finnish medical technology company Nexstim has registered 502,500 new shares with the Finnish Trade Register following investments from Eiffel Investment Group and Brainlab SE. Eiffel invested €3.4 million for 446,459 shares, whilst Brainlab invested €0.4 million for 56,041 shares. Additionally, Eiffel exercised 263,091 option rights and other option holders exercised 74,372 option rights, resulting in 337,463 new shares being registered. The new shares began trading on Nasdaq First North Growth Market Finland alongside existing shares. Following the registrations, Nexstim's total share count stands at 8,074,859. The company develops navigated transcranial magnetic stimulation technology for brain diagnostics and therapy, with FDA-cleared systems for pre-surgical brain mapping and treating major depressive disorder.

MarketScreener
May 25th, 2026
Nexstim registers $4.3M investment from Eiffel and Brainlab, issues 840K new shares

Finnish medical technology company Nexstim has registered 840,000 new shares with the Finnish Trade Register following recent investments and option exercises. The company issued 502,500 shares to Eiffel Investment Group (€3.4 million) and Brainlab SE (€0.4 million), registered on 18 May and trading from 20 May. Additionally, 337,463 shares were issued through option exercises, including 263,091 by Eiffel and 74,372 by existing option holders, registered on 22 May and trading from 25 May. Following these registrations, Nexstim's total share count stands at 8,074,859. The company develops navigated transcranial magnetic stimulation technology for brain diagnostics and therapy, with its NBS System 6 FDA-cleared for pre-surgical brain mapping and treating major depressive disorder and obsessive compulsive disorder.

FinanzNachrichten.de
May 14th, 2026
Nexstim Oyj: Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain Option Holders

Company Announcement, Helsinki, 13 May 2026 at 09:05 AM (EEST) Inside Information: Nexstim Plc Announces EUR 5 Million Investment from Eiffel and from Brainlab and Conversion of Options by Certain Option

AD HOC NEWS
May 13th, 2026
AB S.A. secures $5.6M investment from Eiffel and Brainlab to boost healthcare IT expansion

AB S.A., a Polish healthcare technology company, has secured €5 million in investment from Eiffel Investment Group and Brainlab. The funding coincides with option conversions by certain holders, strengthening the company's financial position. AB S.A. operates in the healthcare technology sector, providing software solutions including electronic health records, practice management systems and telehealth platforms for medical practices and laboratories. The company generates revenue through subscription-based software and services, primarily serving markets across Poland and Europe. The investment signals investor confidence in AB S.A.'s growth prospects within the European healthcare IT sector. The capital will support product development and market expansion efforts as the company benefits from ongoing digitalisation trends in European healthcare.

Business Wire
Feb 25th, 2026
Brainlab and Precision NeuroMed partner to develop AI-enabled drug delivery platform for brain diseases

Brainlab and Precision NeuroMed have formed a strategic partnership to develop an AI-enabled treatment planning platform for convection enhanced delivery (CED) to the brain. Brainlab has taken an equity stake in the clinical-stage biotechnology company as part of the collaboration. The partnership aims to create a cloud-based CED Treatment Planning System that combines Brainlab's medical imaging expertise with Precision NeuroMed's molecular flow simulation software. The platform will use advanced imaging and AI-driven optimisation to personalise drug distribution, overcoming blood-brain barrier limitations that restrict most systemically administered drugs. Initial development will focus on supporting Precision NeuroMed's lead drug, PNM-201, for recurrent glioblastoma. The companies plan to expand the platform to enable delivery of therapies for epilepsy, Parkinson's disease, Alzheimer's disease and ALS.

INACTIVE